Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sage Therapeutics, Inc. - Common Stock (NQ: SAGE )

7.845 -0.005 (-0.06%)
Streaming Delayed Price Updated: 10:58 AM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Sage Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
A Glimpse Into The Expert Outlook On Sage Therapeutics Through 7 Analysts
Via Benzinga
What To Expect From Alzheimer's Drugmaker Biogen's Q4 Earnings On Wednesday?
Biogen faces revenue challenges as Leqembi sales lag projections. Investors watch its pipeline expansion and strategic moves amid upcoming Q4 earnings. 
Via Benzinga
Deal Dispatch: Sage And Silvus Are Up For Sale, MrBeast Secures $20B For TikTok
Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids on TikTok. 
Via Benzinga
Biogen Rises On FDA Nod for Alzheimer's Drug Dosing Regimen, But Sage Deal Fallout Irks Retail
The small-cap biotech firm called the proposal "significantly undervaluing" the company and added that it was not in the best interest of its shareholders. 
Via Stocktwits
Exposures Product Safety
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt
Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company. 
Via Benzinga
Topics Government
Exposures Political
Where Sage Therapeutics Stands With Analysts
Via Benzinga
Earnings Scheduled For February 11, 2025
Via Benzinga
Where Sage Therapeutics Stands With Analysts
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Sage Therapeutics
Via Benzinga
Sage Therapeutics's Earnings: A Preview
Via Benzinga
Sage Therapeutics Stock Eyes Best Day In 5 Years On Biogen’s Unsolicited Bid: Retail Piles In
The two companies have collaborated since 2020 on the depression drug Zurzuvae, approved in 2023 by the FDA for treating postpartum depression. 
Via Stocktwits
Exposures Product Safety
Biogen Bid For Sage Therapeutics Could Strengthen Neurology Strategy: Analysts
Biogen proposes acquiring Sage Therapeutics for $7.22 per share, as analysts highlight the strategic value of Zurzuvae's success in postpartum depression. 
Via Benzinga
Crude Oil Surges 3%; Abercrombie & Fitch Shares Plunge
Via Benzinga
Exposures Fossil Fuels
Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Monday
Via Benzinga
Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?
Sage Therapeutics reviews Biogen's $7.22 per share acquisition proposal amid ongoing restructuring and focus on Zurzuvae for postpartum depression. 
Via Benzinga
The Analyst Verdict: Sage Therapeutics In The Eyes Of 13 Experts
Via Benzinga
Expert Outlook: Sage Therapeutics Through The Eyes Of 14 Analysts
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket
Via Benzinga
This Palo Alto Networks Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Via Benzinga
After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder
Sage Therapeutics ends dalzanemdor development after Phase 2 trials for Huntington's and Alzheimer's fail to meet primary endpoints. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce
Sage Therapeutics announces reorganization, including layoffs and pipeline changes, to support the launch of Zurzuvae. Focus shifts to Huntington's Disease trial after setbacks in essential tremor and... 
Via Benzinga
Topics Workforce
Exposures Layoff
Netflix To $650? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study
Sage Therapeutics' dalzanemdor failed to show significant results in Phase 2 Alzheimer's study. The company discontinues Alzheimer's development but expects Huntington's data soon. Stock drops 10.7%. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Rivian Automotive Cuts Production Outlook, Joins EVgo And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate
Sage Therapeutics announced Biogen's decision to terminate their collaboration on SAGE-324 following negative results from a Phase 2 study, with Sage resuming full ownership of the asset by February... 
Via Benzinga
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.